|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 89.18 CHF | -0.91% |
|
+4.43% | +5.24% |
| 08:14am | NOVARTIS AG : Receives a Buy rating from Jefferies | ZD |
| Apr. 24 | BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating | MT |
ZURICH (Reuters) - Novartis's research head expects an alliance with a University of California chemistry lab to produce drug candidates within three years as the Swiss company accelerates its hunt for new medicines.
Novartis announced the Novartis-Berkeley Centre for Proteomics and Chemistry Technologies on Thursday. It did not give financial details but said the multi-year deal targets "undruggable illnesses" like cancers that have eluded treatments.
(Reporting by John Miller; editing by Brenna Hughes Neghaiwi)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 394.1 USD | -0.14% | -1.63% | 110B | ||
| 99.49 CHF | -0.01% | +1.20% | 31.64B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +5.24% | 201B | |
| +24.35% | 653B | |
| +25.54% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.04% | 233B | |
| -9.98% | 193B | |
| -6.47% | 144B | |
| -12.26% | 143B |
NOVARTIS AG 
